Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B BuseSatish K GargJulio RosenstockTimothy S BaileyPhillip BanksBruce W BodeThomas P A DanneJake A KushnerWendy S LanePablo LapuertaDarren K McGuireAnne L PetersJohn ReedSangeeta SawhneyPaul StrumphPublished in: Diabetes care (2018)
In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer episodes of severe hypoglycemia, improved patient-reported outcomes, and more DKA relative to placebo (ClinicalTrials.gov, NCT02384941).